Status:
COMPLETED
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
Lead Sponsor:
Ophthalmic Consultants of Boston
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Choroidal Neovascularization
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.
Eligibility Criteria
Inclusion
- active choroidal neovascularization
Exclusion
- pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00395551
Start Date
December 1 2005
End Date
June 1 2009
Last Update
January 8 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.